The relationship of regional hemoglobin A1c testing and amputation rate among patients with diabetes

Karina A Newhall1,2, Kimon Bekelis3, Bjoern D Suckow4, Daniel J Gottlieb5, Adrienne E Farber5, Philip P Goodney2,4,5 and Jonathan S Skinner5

Abstract

Objective: The risk of leg amputation among patients with diabetes has declined over the past decade, while use of preventative measures—such as hemoglobin A1c monitoring—has increased. However, the relationship between hemoglobin A1c testing and amputation risk remains unclear.

Methods: We examined annual rates of hemoglobin A1c testing and major leg amputation among Medicare patients with diabetes from 2003 to 2012 across 306 hospital referral regions. We created linear regression models to study associations between hemoglobin A1c testing and lower extremity amputation.

Results: From 2003 to 2012, the proportion of patients who received hemoglobin A1c testing increased 10% (74% to 84%), while their rate of lower extremity amputation decreased 50% (430 to 232/100,000 beneficiaries). Regional hemoglobin A1c testing weakly correlated with crude amputation rate in both years (2003 R = 0.20, 2012 R = 0.21), and further weakened with adjustment for age, sex, and disability status (2003 R = 0.11, 2012 R = 0.17). In a multivariable model of 2012 amputation rates, hemoglobin A1c testing was not a significant predictor.

Conclusion: Lower extremity amputation among patients with diabetes nearly halved over the past decade but only weakly correlated with hemoglobin A1c testing throughout the study period. Better metrics are needed to understand the relationship between preventative care and amputation.

Keywords

Diabetes, glycosylated hemoglobin, amputation

Introduction

Nearly all professional societies recommend regular hemoglobin A1c testing for patients with diabetes.1 These recommendations are based on evidence suggesting that good glycemic control—as measured by hemoglobin A1c levels—can lead to fewer microvascular complications, including amputations.2–4 The National Quality Forum endorses hemoglobin A1c testing rate as a measure of physician quality. It is currently used as a performance standard in Accountable Care organizations and has been cited as a proposed measure by the Centers for Medicare and Medicaid services in 2014.5–7

Hemoglobin A1c is an excellent marker of disease control in diabetes. However, a direct link between the level of quality of diabetic care—as measured by hemoglobin A1c—and amputation risk has yet to be documented in large cohorts. Meta-analysis of quality of care indicators failed to show a significant improvement in patient outcomes.8 However, smaller studies have shown improved outcomes in patients with diabetes, whose physicians utilize quality measures.9,10 Furthermore, earlier regional analyses by our

1Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
2VA Outcomes Group, White River Junction Veterans Hospital, White River Junction, VT, USA
3Section of Neurosurgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
4Section of Vascular Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
5The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, USA

Corresponding author:
Karina Newhall, Department of Surgery, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA.
Email: Karina.A.Newhall@hitchcock.org
group have shown improved vascular outcomes with quality diabetic care.\textsuperscript{11}

In this large analysis, we sought to examine the relationship between the use of hemoglobin A1c testing and amputation risk using a large national dataset that would be adequately powered to examine this question in real-world practice. We examined this relationship over time, hypothesizing that higher hemoglobin A1c testing rates in recent years would be correlated with lower amputation rates, within the hospital referral regions (HRRs) as defined in the Dartmouth Atlas of Healthcare.

**Methods**

**Cohort definition**

Using Medicare Physician and Supplier file as well as the Medicare Denominator file, we identified all patients with diagnostic codes indicative of diabetes between 2003 and 2012. We included patients over age 65 who had been diagnosed with diabetes in the preceding year. Patients remained in our cohort as long as they had a diagnosis code for diabetes in two of three consecutive years. We excluded patients not enrolled in fee-for-service Medicare or who were not enrolled in parts A and B for the entire year. Additional information, including age, sex, and race, were obtained from the Medicare Denominator file.

We then calculated regional rates of diabetes in 2003 and 2012 using patient zip code to create 306 HRR, as described by the Dartmouth Atlas of Health Care.\textsuperscript{12} The denominator was the mid-year population of beneficiaries within the region. Patients aged less than 65, or with missing or incomplete data were excluded from the analysis.

In this analysis, we present our findings from the years at the beginning (2003) and end (2012) of our analytic period. Analyses including all years were also performed, and yielded linear changes in these variables, and therefore for clarity we present only the first and last years in the analyses described in this report.

**Hemoglobin A1c testing**

Within each HRR, we examined the proportion of diabetic patients who received one or more hemoglobin A1c test(s) within the year of interest. CPT codes were used to identify hemoglobin A1c testing, as described by Yasaitis, et al.\textsuperscript{13}

**Defining regional rates of amputation**

Next, within each hospital referral region, we examined the proportion of patients with diabetes who underwent major lower extremity amputations. Amputation was defined as at least one inpatient hospital claim indicating the procedure within each study year: 2003 or 2012. We studied only the first amputation per patient per year. We recorded the most proximal amputation. In the claims data, we could not distinguish between right and left side procedures. For example, if a patient underwent both a toe amputation and an above-knee amputation in a particular year, only the above-knee amputation was recorded. Toe and forefoot amputations were excluded from the primary analysis, as they carry less of a disability burden. However, when we re-ran our analysis including all amputations, the results were similar (Supplementary Figure). Traumatic amputations were excluded.

**Statistical analysis**

We used simple linear regression models to correlate the crude relationship between regional rates of hemoglobin A1c testing and the primary outcome—lower extremity amputation—among patients with diabetes. Pearson correlation coefficient was calculated to determine the strength of the correlation with an associated $p$-value for the linear regression.

Based on the range of rates of diabetics receiving hemoglobin A1c testing in the past year, we assigned each HRR to a quintile of hemoglobin A1c testing: in 2003, the lowest quintile contained HRRs where 41 to 70\% of diabetics had received hemoglobin A1c testing, and the highest quintile contained HRRs where 79 to 87\% of diabetics had received hemoglobin A1c testing in the past year. We then calculated the average amputation rate within each quintile. We then examined the relationship between regional rates of hemoglobin A1c testing and amputation rates, adjusting the amputation rates for regional differences in age, gender, and disability status.

**Risk adjustment**

In an attempt to adjust for confounding by regional-level variables, we created multiple linear regression models to predict 2012 amputation rates, adjusting for regional baseline demographics and rates of health co-morbidities along with regional testing rates. All analyses were performed using SAS (College Station, TX). The Geisel School of Medicine Center for the Protection of Human Subjects granted IRB exemption for this study. Patient consent was not obtained as all conditions for waiver of consent as outlined by the policy of protection of human research subjects were met.
Results

Regional variation in hemoglobin A1c testing rates in 2003 and in 2012

Overall, 73.9% of patients with diabetes received hemoglobin A1c testing in 2003. This number increased to 83.8% in 2012. As regions increased their hemoglobin A1c testing, the degree of variation among regions decreased. In 2003, the highest testing region performed testing over twice as often as the lowest-testing region: 87.5% (Whitefield, WI) to 41.5% (Oxford, MS). In 2012, this variation had decreased to 30%: 93% (Dubuque, IA) to 68.4% (Albuquerque, NM).

Regional variation in lower extremity amputation rates in 2003 and in 2012

The national rate of lower extremity amputation fell from 431 per 100,000 beneficiaries in 2003 to 232 per 100,000 in 2012. Despite this trend, there was almost a 10-fold variation across HRRs (Figure 1). Crude amputation rates in 2003 varied from near 0 (Grand Junction, CO) to 1210 per 100,000 beneficiaries (Corpus Christi, TX) in 2003. This variation persisted in 2012, when amputation rates ranged from 48 per 100,000 (Great Falls, MT) to 501 per 100,000 (Corpus Christi, TX).

Characteristics of patients with diabetes, by testing quintile

We examined the characteristics of patients with diabetes living in quintiles of regions with lowest to highest rates of hemoglobin A1c testing in 2012 (Table 1). Each quintile contained approximately 2.3 million beneficiaries with diabetes. Quintiles were similar in terms of age and gender, smoking, and overall comorbidities. However, quintiles of regions with lower rates of hemoglobin A1c testing have a higher percentage of racial and ethnic minorities. For example, the lowest quintile has 50% more African Americans (12.3 vs. 7.4%) and over six-fold more Hispanic patients than the highest quintile (6.1 vs. 0.5%). Given the very large size of the cohort, all differences between the quintiles reach

Figure 1. Regional variation in amputation rate in patients with diabetes, over age 65: 2012.
statistical significance. Although patients in the highest quintile have an increased percentage of patients with renal disease and peripheral vascular disease, these differences were not clinically significant, as most represent absolute differences of less than 1–2%.

**Association between hemoglobin A1c testing and amputation**

We found a weak inverse correlation between regional hemoglobin A1c testing and lower extremity amputation in 2003 ($R = -0.20$) and in 2012 ($R = -0.21$, Figure 2). That is—regions with higher testing had lower rates of amputation among patients with diabetes. When amputation rates were adjusted for demographic regional differences (age, sex, disability status), this relationship was attenuated in both 2003 ($R = -0.11$) and 2012 ($R = -0.17$, Figure 3). The strongest relationship was between 2003 testing rates and 2012 amputation rates ($R = -0.27$), which remained relatively unchanged with adjustment for amputation rates ($R = -0.22$).

Next, we examined these relationships by quintile of hemoglobin A1c testing (Figure 4). In 2003, we found that regions with the lowest hemoglobin A1c testing rates (41–70% of patients with diabetes) had 40% more lower extremity amputations than those within the highest strata of testing (460 vs. 349 per 100,000). In 2012, despite increases in hemoglobin A1c testing and decreases in lower extremity amputation, the lowest strata of testing still had 27% more lower extremity amputations than the highest (261 vs. 206 per 100,000).

In multivariate linear regression adjusting for regional differences in age, sex, race, income, and comorbidities, regional rates of hemoglobin A1c testing were not predictive of 2012 amputation rate (Supplementary Table 2). Significant predictors of amputation rate were limited to 2003 amputation rate and female gender.

**Discussion**

In recent years, hemoglobin A1c testing rates have increased because of an emphasis on adherence to preventive guidelines that include hemoglobin A1c testing rates as a standard measure. At the same time, we found in nearly every region of the United States, amputation rates have fallen over the last decade. While many have presumed that these two events are related, our observational evidence fails to directly support this presumption. In both 2003 and 2012, there was a weak inverse correlation between regional rates of hemoglobin A1c testing and lower extremity amputation rates. However, after adjusting for regional age, gender and disability, hemoglobin A1c testing rates were not associated with amputation rates in 2012.

### Table 1. Characteristics of patients with diabetes living in quintiles of regions with lowest to highest rates of hemoglobin A1c testing in 2012. (Total $n = 11,943,000$).

<table>
<thead>
<tr>
<th>Quintile</th>
<th>Age, mean (SD)</th>
<th>Gender (% female)</th>
<th>African American, %</th>
<th>Hispanic, %</th>
<th>Medicaid, %</th>
<th>Charlson Score 2003, mean (SD)</th>
<th>Charlson Score 2012, mean (SD)</th>
<th>Renal disease, %</th>
<th>Peripheral vascular disease, %</th>
<th>Obese, BMI &gt;30, %</th>
<th>Smoker, %</th>
<th>Median household income, US $ (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lowest (68–81%)</td>
<td>75.5 (7.0)</td>
<td>55.8</td>
<td>12.3</td>
<td>6.1</td>
<td>29.3</td>
<td>1.4 (2.0)</td>
<td>1.7 (2.2)</td>
<td>12.4</td>
<td>12.9</td>
<td>27.8</td>
<td>19.0</td>
<td>50,996 (20,614)</td>
</tr>
<tr>
<td>(n = 2,332,262)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (81–83%)</td>
<td>75.8 (7.0)</td>
<td>56.3</td>
<td>15.4</td>
<td>1.6</td>
<td>19.1</td>
<td>1.5 (2.0)</td>
<td>1.7 (2.2)</td>
<td>12.0</td>
<td>12.0</td>
<td>28.8</td>
<td>19.7</td>
<td>57,250 (24,091)</td>
</tr>
<tr>
<td>(n = 2,401,512)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average (83–84%)</td>
<td>75.7 (7.0)</td>
<td>55.2</td>
<td>12.0</td>
<td>2.3</td>
<td>18.2</td>
<td>1.5 (2.0)</td>
<td>1.7 (2.2)</td>
<td>12.1</td>
<td>12.1</td>
<td>28.9</td>
<td>20.2</td>
<td>54,676 (22,669)</td>
</tr>
<tr>
<td>(n = 2,383,574)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High (85–86%)</td>
<td>75.9 (7.0)</td>
<td>54.6</td>
<td>10.7</td>
<td>1.2</td>
<td>16.7</td>
<td>1.4 (1.9)</td>
<td>1.6 (2.2)</td>
<td>11.4</td>
<td>11.4</td>
<td>28.5</td>
<td>20.0</td>
<td>52,401 (17,918)</td>
</tr>
<tr>
<td>(n = 2,358,147)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Highest (&gt;86%)</td>
<td>76.0 (7.1)</td>
<td>54.9</td>
<td>7.4</td>
<td>0.5</td>
<td>16.5</td>
<td>1.3 (1.9)</td>
<td>1.6 (2.1)</td>
<td>11.4</td>
<td>11.4</td>
<td>28.5</td>
<td>20.0</td>
<td>52,458 (17,559)</td>
</tr>
<tr>
<td>(n = 2,467,505)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p-value by simple test of trend.*
Our study adds a population-level perspective to already published evidence on this topic. Multiple trials have shown a strong correlation with good glycemic control and reduction in overall macrovascular complications in individual patients.\textsuperscript{2–4,14} Furthermore, studies examining the relationship of physician and system performance metrics on patient level outcomes have found modest correlation. A case control study comparing Medicare patients with lower extremity amputations to those without in West Virginia found an association with physician diabetic care quality measures—such as rates of annual hemoglobin A1c testing and amputation rates.\textsuperscript{9} Earlier work has found patients with diabetes who undergo revascularization procedures in high-testing areas enjoy longer amputation-free survival than those in lower testing areas.\textsuperscript{11}

In a systematic review and meta-analysis of the topic, however, Sidorenkov et al.\textsuperscript{8} failed to show a relationship between hemoglobin A1c testing among physicians and bad outcomes—such as lower extremity amputations. Furthermore, a review of system-wide quality initiatives in the Kaiser-Permanente Health care system in the mid-1990s found little association with increased frequency of all diabetic

---

**Figure 2.** Crude association of regional hemoglobin A1c testing rates and amputation 2003 and 2012.

**Figure 3.** Association of regional hemoglobin A1c testing rates and adjusted\textsuperscript{1} amputation rates: 2003 and 2012.

\textsuperscript{1} Amputation rate adjusted for regional differences in age, gender, and disability status.
testing—including hemoglobin A1c—and lower extremity amputation, though increased levels of testing were strongly associated with more intensive medical therapy. Our study supports these findings with population-level analysis: annual hemoglobin A1c testing as a process measure of diabetic care quality does not strongly correlate with decreased amputation risk.

Current physician and system-level metrics of diabetic care quality—as measured by hemoglobin A1c testing—do not correlate well with decreases in amputation. We hypothesize that these annual measures do not fully capture the complexity of care for the patient with diabetes. A variety of factors—patient participation, adherence, and the longitudinal quality of care for patients with diabetes all are likely to explain differences in vascular outcomes such as amputation. Many argue, in fact, that successful prevention strategies are longitudinal in nature. Studies have found various measures of care intensity, such as primary care visit frequency or regular hemoglobin A1c testing, are associated with improvements in glycemic control. Such measures—while more complex to obtain—would better encompass quality of care obtained by a patient with diabetes, and likely show a closer association with outcomes.

**Limitations**

Our study has several limitations. As a retrospective analysis of administrative claims, it lacks clinical detail. Most notably, we do not know the average value of the hemoglobin A1c was in any of the testing regions. Because recommended quality metrics similarly do not specify target values, the use of claims data is well suited to this study aim. Second, our analysis was performed on a regional level and could not fully adjust for differences in socioeconomic characteristics and access to care that may exist among different HRRS. Third, as a cross-sectional study a decade apart, we do not know the temporal relationship of hemoglobin A1c testing and amputation prevention. Future work will focus on this relationship on an individual level. Lastly, we were limited in our ability to evaluate improvements in preventative care overall. These improvements have been hypothesized to be a key driver in decreases in complications from diabetes. Our findings would support this hypothesis, given that overall amputation rates have improved.

**Conclusion**

Patients with diabetes living in regions with high hemoglobin A1c testing rates have a better chance of avoiding amputation than those that live in a region where testing is not as frequent. However, improvements in annual hemoglobin A1c testing rate do not reflect improvements in diabetic care quality within a region. In order to more effectively reduce amputation rates within at-risk regions, more focus should be placed on improving metrics to better understand relationships between the quality of care provided to patients with diabetes and cardiovascular outcomes such as amputation.

**Acknowledgements**

This study was presented as a mini-presentation (entitled “What matters most in limiting amputation among Diabetics: where you start, where you finish or how much you improve?”) in Lower Extremity Session, Society for Clinical Vascular Surgery annual meeting 30 March–1 April 2015 (Miami, FL).
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
This research was supported through NIH grant 1U01AG046830-01 (Technology Diffusion, Health Outcomes, and Health Expenditures, Jonathan Skinner, PI)

References